New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
07:01 EDTSNTSSantarus initiates Phase IIa study with SAN-300 in patients with active RA
Santarus announced that it has begun patient enrollment in a multicenter, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose study with the investigational drug SAN-300, its novel antibody that inhibits very late antigen-1. The Phase IIa study is designed to evaluate the safety and tolerability of repeat subcutaneous doses of SAN-300 in patients with active rheumatoid arthritis with inadequate response to disease-modifying anti-rheumatic drugs. Approximately 90 patients will be enrolled in the study.
News For SNTS From The Last 14 Days
Check below for free stories on SNTS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SNTS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use